We report a patient with pre-existing end-stage renal disease (ESRD) who underwent successful matched related donor allogeneic bone marrow transplantation for AML in second complete remission (CR2) using conditioning with high-dose cyclophosphamide (CY, 60 mg/kg/day ؋ 2) and TBI (165 cGy twice daily ؋ 4 days). The timing of hemodialysis after high-dose CY was extrapolated from available data on the pharmacokinetics of high-dose CY and hemodialysis clearance of conventional dose CY and its metabolites. Pharmacokinetic analyses indicated that the elimination of highdose CY and its alkylating metabolites is impaired in ESRD but is cleared with hemodialysis. The patient's early post-transplant course was uncomplicated, and WBC and platelet engraftment occurred by day ؉22. Bone marrow examination on day ؉25 showed trilineage engraftment with no AML; cytogenetics showed 100% donor karyotype. The patient remains in remission with 100% donor karyotype at 3 years post transplant. Clinical results indicate that the administration of high-dose CY is feasible with hemodialysis support for patients with ESRD. Keywords: allogeneic BMT; renal disease; cyclophosphamide; AML; pharmacokinetics; hemodialysis High-dose chemotherapy with BMT is considered to be contraindicated in patients with severe renal dysfunction since it is often assumed that the pharmacokinetics and/or pharmacodynamics of high-dose chemotherapy are significantly altered. High-dose cyclophosphamide (CY) is a common component of preparative regimens. The effect of renal dysfunction on the pharmacokinetics of high-dose CY is not known although pharmacokinetic models suggest that Correspondence: Dr JJ Perry, Section of Hematology/Oncology, Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, USA 27157 Received 9 July 1998; accepted 12 November 1998 clearance of two important CY metabolites, 4-OH CY and aldophosphamide, may be reduced if severe renal impairment is present.
clearance of two important CY metabolites, 4-OH CY and aldophosphamide, may be reduced if severe renal impairment is present. 1 The pharmacokinetics of conventionaldose CY and its alkylating metabolites are altered in patients with renal insufficiency. 2, 3 However, the toxicity profile has not been reported to be different from patients with normal renal function 4 leading some authors to suggest that conventional doses of CY do not require modification in patients with renal dysfunction. 5 In this report, we describe the clinical BMT course of a patient with endstage renal disease (ESRD) (on chronic hemodialysis) and AML in CR2 who received high-dose CY. The pharmacokinetics of high-dose CY and CY-alkylating metabolites are also presented.
Case report
A 42-year-old male was diagnosed with AML (subtype FAB-M2) in January 1994. He achieved CR after treatment with daunorubicin 45 mg/m 2 i.v. × 3 days and cytarabine 100 mg/m 2 /day by continuous i.v. infusion (CIVI) ϫ 7 days. He was given four courses of post-remission therapy using daunorubicin 45 mg/m 2 i.v. ϫ 2 days and cytarabine 100 mg/m 2 /day CIVI ϫ 5 days, completed in July 1994. Bone marrow examinations performed at intervals during and after post-remission therapy continued to confirm CR. In December 1994, he was found to have relapsed in the bone marrow on routine follow-up. He achieved CR2 after re-induction therapy with mitoxantrone 12 mg/m 2 i.v. ϫ 3 days and cytarabine 100 mg/m 2 /day CIVI × 7 days. He also received a course of post-remission therapy with mitoxantrone 12 mg/m 2 i.v. ϫ 2 days and cytarabine 100 mg/m 2 /day CIVI × 5 days. 6 Both induction courses were well tolerated.
He had dialysis-dependent ESRD secondary to hypertension and nephrosclerosis, occurring 2 years prior to the diagnosis of AML. He was briefly on peritoneal dialysis which was unsuccessful. He had been on a stable hemodialysis schedule (three times weekly) at the time of the diagnosis of AML. Plans for a renal transplant were deferred when the diagnosis of AML was made. He required ongo-ing medical therapy for control of hypertension. Past medical history was otherwise unremarkable and he was in good physical condition at the time of BMT referral. Medication included clonidine 0.3 mg p.o. three times a day, lisinopril 20 mg p.o. twice a day, labetalol 200 mg p.o. twice a day, calcium acetate 1 p.o. four times a day, ranitidine 150 mg p.o. every day, and erythropoietin 10 000 units s.q. weekly. Pre-transplant renal function parameters (on three times weekly hemodialysis) included serum creatinine 707-972 mol/l, BUN 14-25 mmol/l, and urine volume 250 ml/24 h. On HLA typing, the patient and his 44-yearold sister were serologically matched at the HLA-A,B, and DR loci. Both were CMV antibody positive.
The patient was offered the option of matched related donor allogeneic BMT after extensive discussion of the potential benefits, risks and alternatives. He was fully appraised of the unique nature of his case and the apparent lack of precedent for the administration of high-dose CY in the setting of pre-existing hemodialysis-dependent ESRD. Potential concerns discussed with the patient included possible graft failure from the lack of an immunosuppressive effect if CY and CY-alkylating metabolites were too rapidly cleared by hemodialysis or failure to engraft or severe CY-related toxicity (notably cardiac or bladder) if hemodialysis clearance was poor. The BMT process proceeded with full patient consent and was approved by the local Institutional Review Board under 'Innovative Practice' guidelines.
Conditioning regimen and hemodialysis schedule
The conditioning regimen was CY 60 mg/kg (actual body weight) i.v. over 2 h at 1600 h on day −7 and day −6, and TBI 165 cGy twice a day ϫ 4 days (day −4 to day −1). The patient had his regular hemodialysis session (4 h) on day −7 before CY. Longer hemodialysis sessions (6 h each) were performed beginning 14 h after the end of each of the 2-h CY infusions, starting at 0800 h on days −6 and −5. Regular 4-h hemodialysis sessions were resumed on day −4, then three times weekly, until hospital discharge. Hemodialysis was performed prior to marrow infusion on day 0. The patient's left upper extremity arterio-venous fistula was used for dialysis access until day −4, when a hematoma developed at the fistula site. A right internal jugular doublelumen temporary vascular catheter was then used for hemodialysis access until day +14. Hemodialysis was performed using a Terumo T-220 dialyzer, using bicarbonate dialysis, with a dialysate flow of 500 ml/min and a blood flow rate between 300 and 400 ml/min.
Pharmacokinetic studies
Venous blood samples were collected at 0, 1, 2, 3, 4, 6, 12 and 24 h after the start of each CY infusion. With the second (and last) CY infusion, samples were collected at the above times and at 96 and 120 h. Blood samples were also collected at pre-and post-dialysis (for the day −6 and day −5 sessions after CY). Arterial and venous (dialysate) samples were obtained prior to, during, and immediately after hemodialysis on day −6. All samples were collected in tubes containing semicarbizide, 7 immediately placed on ice, and transported to the laboratory for centrifugation (2000 g, 4°C, 10 min). Samples were analyzed for plasma concentrations of CY and CY-alkylating activity. Plasma concentrations of CY were determined by a HPLC method, as previously described. 8 Plasma CY-alkylating activity was determined by a stable, colorimetric method.
9,10 A standard curve of mechlorethamine (range of 10-100 g/ml) in plasma was prepared and run daily. CY-alkylating activity was reported as g/ml of mechlorethamine equivalents.
Pharmacokinetic analysis of the pre-dialysis CY and CYalkylating metabolite data was performed using weighted, nonlinear, least-squares regression analysis. 11 Pharmacokinetic parameters including half-life, systemic clearance (Cl s ), and the steady-state volume of distribution (Vd ss ) were calculated from the modeled data. Hemodialysis clearance (Cl HD ) of CY was calculated using the equation:
where Q B is blood flow rate, H is hematocrit, K is concentration of drug in red blood cells/concentration of drug in plasma reported previously, 12 C ap is arterial plasma concentration of drug, and C vp is venous plasma concentration of drug. This equation has been previously used by Wang et al 12 to calculate the Cl HD of CY using the partition coefficient of CY in red blood cells. The Cl HD of CY-alkylating metabolites was calculated using the equation:
Marrow infusion and BMT management
ABO-compatible, plasma-depleted bone marrow from the donor was infused on day 0. Nucleated cell dose was 1.76 ϫ 10 8 /kg. The patient underwent 300 ml phlebotomy before infusion of the 580 ml of donor bone marrow to prevent intravascular volume overload.
Continuous bladder irrigation was employed for prevention of hemorrhagic cystitis from day −7 to day −5 (during and for 24 h after CY administration). Minimal i.v. hydration (100 ml/h) was used with the CY administration. Cyclosporine and methylprednisolone were administered as GVHD prophylaxis. The cyclosporine dose was adjusted to maintain therapeutic concentrations. Doses of prophylactic fluconazole and acyclovir were adjusted for renal insufficiency and the hemodialysis schedule. Standard intravenous immunoglobulin dose and schedule were used without modification. Electrocardiograms were performed prior to each CY dose and daily for 4 additional days. Twodimensional surface echocardiogram was performed at baseline and repeated on day −4. Prophylactic platelet transfusions were administered for platelet counts Ͻ20 × 10 9 /l.
Results

Clinical course
The conditioning regimen administration was uncomplicated. There were no acute cardiac effects detected by physical examination, electrocardiogram, or echocardiogra-phy. No hemorrhagic cystitis was observed. Donor bone marrow infusion was uncomplicated. Mucositis was minimal, and hyperalimentation was not required. The patient was able to maintain his three times weekly 4-h hemodialysis schedule throughout hospitalization; continuous dialysis was not required. The usual degree of peripheral blood pancytopenia occurred, requiring platelet and RBC transfusion support. Peripheral blood neutrophils were noted by day +11, and the absolute neutrophil count exceeded 500/l by day +16. No excessive bleeding was noted post transplant due to either qualitative or quantitative platelet abnormalities. No platelet transfusions were required after day +21.
Regarding infectious complications, neutropenic fever developed on day +4 and blood cultures showed a coagulase-negative Staphylococcal species. This responded to antibiotic therapy with ceftazidime and vancomycin. Fevers returned on day +11 and there was no response to empiric amphotericin B therapy. Fevers resolved after removal of the temporary right internal jugular vascular access catheter on day +14; the catheter tip cultures grew coagulase-negative Staphylococci. Intravenous antimicrobials were discontinued on day +21 and the patient was discharged on day +26. Bone marrow examination on day +26 showed trilineage engraftment with no evidence of leukemia. Cytogenetics showed 100% female cells.
His post-transplant course after discharge was complicated by CMV infection on day +46 with positive blood and urine cultures. He was given a 14-day course of ganciclovir therapy with clearance of the CMV viremia and viruria; ganciclovir was continued two to three times weekly post-hemodialysis until day +100. He developed neutropenia from the ganciclovir therapy which responded to G-CSF therapy; he did not require platelet transfusions.
He developed mild chronic graft-versus-host disease (skin, oral cavity) 6 months post transplant after discontinuation of prophylactic prednisone. He is currently being managed with azathioprine and alternate-day prednisone. Bone marrow examination at 24 months post transplant indicates trilineage hematopoiesis without leukemia, with 100% 46XX (donor karyotype) cells by cytogenetics. His Karnofsky performance status is 90% and he is under consideration for renal transplantation.
Pharmacokinetic studies
A one-compartment model was determined to best fit the CY and CY-alkylating plasma concentration-time data. The plasma concentration-time profile of CY and CY alkylating activity is shown in Figure 1 . Pharmacokinetic parameters for CY on day 1 and day 2 prior to hemodialysis on each day were elimination t 1/2 14.6 and 9.0 h, Cl s 38.4 and 48.5 ml/min, and Vd ss 49.5 and 40.5 l, respectively. The CY-alkylating elimination half-life was 22.4 and 16.5 h after the first and second doses, respectively. During hemodialysis on day 1, the CL HD of CY and CY-alkylating metabolites were 178 and 108 ml/min, respectively. Plasma samples collected at 96 and 120 h from the start of the second CY dose administration indicated no measurable CY while the plasma CY-alkylating activity was at the limit of assay sensitivity (Figure 1 ). 
Discussion
We report the safe and effective use of high-dose CY in a patient with ESRD receiving hemodialysis. Ballester et al 13 have also reported the safe administration of high-dose CY (along with busulfan) in patients with ESRD undergoing BMT. The use of high-dose CY in this setting is of concern since delay in the clearance of CY or CY metabolites may increase the patient's risk of developing cardiotoxicity, suppression of donor marrow, and other life-threatening toxicities. In patients with normal organ function, the pharmacokinetics of high-dose CY has significant interpatient variability and this variability is correlated with survival and cardiotoxicity. 14 The systemic clearance of high-dose CY in our patient, determined prior to hemodialysis, was 38.4 ml/min, which is lower than in patients with normal renal function (normal range 51-100 ml/min). 1, 7, 15, 16 Following the administration of conventional or high-dose CY, approximately 50% of the dose is eliminated in the urine within 24 h, with 20% of the dose eliminated as the parent compound. 17 Substantial interpatient variability in the pharmacokinetics of CY and 4-OH CY is reported in patients receiving high-dose CY. 16 In patients with moderate to severe renal dysfunction, the pharmacokinetics of conventional dose CY are altered. Mouridsen et al 3 reported that following the administration of 14 C-CY to five patients with renal failure (CrCl Ͻ10 ml/min/1.73 m 2 ), 70% of the total radioactivity administered was present 48 h after administration with no radioactivity detected after 24 h in patients with normal renal function. Juma et al 2 evaluated the pharmacokinetics of conventional-dose CY in seven patients with renal dysfunction (CrCl 0-51 ml/min) and in eight patients with normal renal function. The systemic clearance of CY was 58.6 Ϯ 10.9 ml/kg/h in patients with normal renal function vs 48.8 Ϯ 10.9 ml/kg/h in patients with renal dysfunction. However, only two of the seven patients with renal dysfunction had a CrCl Ͻ20 ml/min.
CY and its alkylating metabolites were effectively cleared by hemodialysis in our patient (hemodialysis clearance of CY and CY-alkylating metabolites were 171 and 108 ml/min, respectively). Wang et al 12 reported that the hemodialysis clearance of conventional dose CY was 104 ml/min and concluded that CY was dialyzable. Wagner et al 18 reported that the CY-alkylating metabolites were effectively eliminated with the use of hemodialysis. Thus, hemodialysis is effective in removing CY and CY-alkylating species whether CY is administered at conventional or high doses which is expected given the low molecular weight and protein binding of CY and CY-alkylating metabolites.
A limitation of the pharmacokinetic data reported in this study is the use of the nitrobenzylpyridine (NBP) assay for estimating CY-alkylating metabolites. This assay has several limitations 19 and provides only an estimation of the alkylating species of CY. Since the conduct of this study, advances in analytical methodology have permitted the pharmacokinetic analysis of high-dose CY and some of its metabolites (4-hydxoxy-CY and aldophosphamide). 1, 16 However, the reliable quantitation of other CY metabolites has proven difficult. 20 In conclusion, the clinical outcome in this case was favorable, and full engraftment was achieved indicating that immunosuppression was adequate. No severe CY toxicities were observed, indicating that clearance of CY and CY metabolites was adequate. Therapeutic efficacy is evident by the patient's sustained CR2 status.
